Kaituo Pharmaceutical-B (09939) rose by more than 8%. As of press release, it rose 7.95% to HK$1.63, with a turnover of HK$1,8021 million.
The Zhitong Finance App learned that Kaituo Pharmaceutical-B (09939) rose by more than 8%. As of press release, it had risen 7.95% to HK$1.63, with a turnover of HK$1,8021 million.
According to the news, Kaituo Pharmaceutical recently announced that a phase IB/III clinical trial of KX-826 combined with minoxidil to treat androgenic alopecia (AGA) in adult Chinese men, developed independently by the company and potentially pioneered by the same company, has recently been approved by the State Drug Administration to evaluate the efficacy and safety of KX-826 and minoxidil in the treatment of male AGA patients in China. The company said it is carrying out and plans to launch multiple clinical trials of KX-826 to treat hair loss and acne, and continue to develop the use value of KX-826 in the dermatological field.